ERBB2 and breast carcinoma: Another phase III trial is evaluating the safety and efficacy of adding nivolumab (anti-PD-1) in the preoperative and adjuvant setting in combination with standard therapy in stage II/III HR+/HER2- breast cancer patients (NCT04109066).